• Following U.S. FDA clearance for the OPTIMA Study earlier this year and with the strong support of the HCC research community, we have been accelerating our efforts in support of clinical trial sites in the other major markets including China, Asia Pacific and the European Union, and are well positioned to enroll our first patient mid-year 2014.The Phase III OPTIMA Study is expected to enroll 55